Initiation of home noninvasive ventilation in hypercapnic chronic obstructive pulmonary disease: when, where, and how?

IF 2.8 3区 医学 Q2 RESPIRATORY SYSTEM
Current Opinion in Pulmonary Medicine Pub Date : 2025-03-01 Epub Date: 2024-11-14 DOI:10.1097/MCP.0000000000001139
Spyridon Fortis, Kathleen F Sarmiento
{"title":"Initiation of home noninvasive ventilation in hypercapnic chronic obstructive pulmonary disease: when, where, and how?","authors":"Spyridon Fortis, Kathleen F Sarmiento","doi":"10.1097/MCP.0000000000001139","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review aims to highlight the importance of timely initiation of home noninvasive ventilation (homeNIV) for patients with chronic hypercapnic respiratory failure (CHRF) due to chronic obstructive pulmonary disease (COPD). As emerging evidence continues to show substantial benefits in reducing mortality and hospitalizations, it's crucial to identify which patients will benefit most and to provide clear guidance on implementing homeNIV effectively.</p><p><strong>Recent findings: </strong>Recent research supports the use of high intensity homeNIV for CHRF secondary to COPD, showing marked reductions in hospitalizations and mortality. However, despite its proven benefits, homeNIV is underutilized, often due to significant barriers related to payor policies and gaps in knowledge by those most likely to be evaluating and managing patients with advanced COPD. The literature also reveals ongoing debate about the optimal timing and setting for starting homeNIV, whether in outpatient clinics or directly after hospital discharge.</p><p><strong>Summary: </strong>The evidence suggests that homeNIV should be more widely used, with a focus on early initiation and careful titration to normalize PaCO 2 over time. By addressing the barriers to its broader use, we can improve outcomes for patients with CHRF due to COPD.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"165-174"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCP.0000000000001139","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: This review aims to highlight the importance of timely initiation of home noninvasive ventilation (homeNIV) for patients with chronic hypercapnic respiratory failure (CHRF) due to chronic obstructive pulmonary disease (COPD). As emerging evidence continues to show substantial benefits in reducing mortality and hospitalizations, it's crucial to identify which patients will benefit most and to provide clear guidance on implementing homeNIV effectively.

Recent findings: Recent research supports the use of high intensity homeNIV for CHRF secondary to COPD, showing marked reductions in hospitalizations and mortality. However, despite its proven benefits, homeNIV is underutilized, often due to significant barriers related to payor policies and gaps in knowledge by those most likely to be evaluating and managing patients with advanced COPD. The literature also reveals ongoing debate about the optimal timing and setting for starting homeNIV, whether in outpatient clinics or directly after hospital discharge.

Summary: The evidence suggests that homeNIV should be more widely used, with a focus on early initiation and careful titration to normalize PaCO 2 over time. By addressing the barriers to its broader use, we can improve outcomes for patients with CHRF due to COPD.

高碳酸血症慢性阻塞性肺疾病的家庭无创通气:何时、何地、如何开始?
综述目的:本综述旨在强调及时启动家庭无创通气(homeNIV)对慢性阻塞性肺疾病(COPD)所致慢性高碳血症性呼吸衰竭(CHRF)患者的重要性。随着新出现的证据继续显示在降低死亡率和住院率方面的实质性益处,确定哪些患者将受益最大,并为有效实施homeNIV提供明确的指导至关重要。最近的发现:最近的研究支持使用高强度homeNIV治疗COPD继发CHRF,显示住院率和死亡率显著降低。然而,尽管homeNIV已被证明具有益处,但它并未得到充分利用,这通常是由于与付款人政策相关的重大障碍以及最有可能评估和管理晚期COPD患者的人的知识差距。文献还揭示了正在进行的关于开始家庭静脉注射的最佳时间和设置的争论,是在门诊诊所还是在出院后直接开始。总结:有证据表明,homeNIV应该更广泛地应用,重点是早期启动和谨慎的滴定,以使PaCO2随着时间的推移正常化。通过解决其广泛应用的障碍,我们可以改善COPD所致CHRF患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
109
审稿时长
6-12 weeks
期刊介绍: ​​​​​​Current Opinion in Pulmonary Medicine is a highly regarded journal offering insightful editorials and on-the-mark invited reviews, covering key subjects such as asthma; cystic fibrosis; infectious diseases; diseases of the pleura; and sleep and respiratory neurobiology. Published bimonthly, each issue of Current Opinion in Pulmonary Medicine introduces world renowned guest editors and internationally recognized academics within the pulmonary field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信